These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22190871)

  • 21. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.
    Henson ES; Johnston JB; Los M; Gibson SB
    Biologics; 2007 Sep; 1(3):229-39. PubMed ID: 19707333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
    Dimri M; Naramura M; Duan L; Chen J; Ortega-Cava C; Chen G; Goswami R; Fernandes N; Gao Q; Dimri GP; Band V; Band H
    Cancer Res; 2007 May; 67(9):4164-72. PubMed ID: 17483327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
    Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
    J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
    Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
    Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology.
    Shyamala G; Chou YC; Cardiff RD; Vargis E
    Cancer Res; 2006 Nov; 66(21):10391-8. PubMed ID: 17079459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
    Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
    Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
    Bui T; Schade B; Cardiff RD; Aina OH; Sanguin-Gendreau V; Muller WJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E707-E716. PubMed ID: 28096336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
    Brandt R; Wong AM; Hynes NE
    Oncogene; 2001 Sep; 20(39):5459-65. PubMed ID: 11571643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ErbB2 is required for ductal morphogenesis of the mammary gland.
    Jackson-Fisher AJ; Bellinger G; Ramabhadran R; Morris JK; Lee KF; Stern DF
    Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17138-43. PubMed ID: 15569931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
    Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
    Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.
    Acharya S; Xu J; Wang X; Jain S; Wang H; Zhang Q; Chang CC; Bower J; Arun B; Seewaldt V; Yu D
    Am J Cancer Res; 2016; 6(5):981-95. PubMed ID: 27293993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.